Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

OptiNose, Inc. (OPTN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.9200-0.0800 (-2.67%)
At close: 4:00PM EDT
2.9200 0.00 (0.00%)
After hours: 05:02PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Previous Close3.0000
Open3.0000
Bid2.9000 x 800
Ask2.9600 x 900
Day's Range2.9100 - 3.0000
52 Week Range2.3200 - 5.1100
Volume105,622
Avg. Volume275,390
Market Cap155.662M
Beta (5Y Monthly)0.93
PE Ratio (TTM)N/A
EPS (TTM)-1.8250
Earnings DateNov 03, 2021 - Nov 08, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for OPTN

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • OptiNose, Inc.
    Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We CoverThis edition features the continuing shift to software; biopharma capital allocation; rising ransomware attacks; and new coverage of Stem, Keysight, and Carlyle Group.
    Rating
    Fair Value
    Economic Moat
    4 days agoMorningstar
View more
  • GlobeNewswire

    Optinose to Present at the Cantor Virtual Global Healthcare Conference

    YARDLEY, Pa., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at the Cantor Virtual Global Healthcare Conference on September 28, 2021, at 8:40 a.m. ET. To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website. A replay of

  • GlobeNewswire

    Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    YARDLEY, Pa., Aug. 25, 2021 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the company has granted non-qualified stock option awards to purchase an aggregate of 60,000 shares of its common stock to seven new employees as an inducement material for accepting employment with OptiNose. The stock option awards were granted outside of the OptiNose, Inc. 2010 Stock Incent

  • Zacks

    OptiNose (OPTN) Reports Q2 Loss, Tops Revenue Estimates

    OptiNose (OPTN) delivered earnings and revenue surprises of -2.33% and 5.84%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Advertisement
Advertisement